

## ALK upgrades its full-year financial outlook due to strong growth

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the company has revised its 2019 financial guidance upwards based on the better than expected results in the first half-year and the forecast for the second half-year.

- ▶ Full-year revenue is now projected to be DKK 3,200-3,300 million (previously: DKK 3,100-3,300 million).
- ▶ Operating profit (EBITDA) is now expected at DKK 150-250 million (previously: DKK 100-200 million).
- ▶ Free cash flow is now expected at approximately DKK minus 300 million (previously: DKK minus 400 million or better).

The revenue update primarily reflects a continued strong growth momentum for SLIT-tablets, while the EBITDA update reflects the expected revenue development and efficiencies. ALK continues its investment programme to support the three-year strategic transformation of the company, and the associated business investments will continue to affect operating profit and free cash flow.

ALK will detail the revised full-year outlook in its six-month interim report (Q2), which will be published tomorrow morning, Tuesday, 13 August 2019, where the company will host a tele conference for analysts and institutional investors at 13.30 p.m. (CEST).

### ALK-Abelló A/S

#### For further information please contact:

*Investor Relations:* Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

*Media:* Jeppe Ilkjær, mobile +45 3050 2014

This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.

#### About ALK

*ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors.*

*Headquartered in Hørsholm, Denmark, ALK employs around 2,400 people worldwide and is listed on Nasdaq Copenhagen. Find more information at [www.alk.net](http://www.alk.net).*